A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy

HIV Clinical Trials

Volumn 11, Issue 1, 2010, Pages 39-50

  Raboud, Janet M ^a,b   Diong, Christina ^b   Carr, Andrew ^c   Grinspoon, Steven ^d   Mulligan, Kathleen ^e   Sutinen, Jussi ^f   Rozenbaum, William ^g   Cavalcanti, Rodrigo B ^a,b   Wand, Handan ^c   Costagliola, Dominique ^h,i   Walmsley, Sharon ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d HARVARD UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF HELSINKI   (Finland)

^g SAINT LOUIS HOSPITAL   (France)

^h INSERM   (France)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

HAART; HIV; Lipoatrophy; Meta analysis; Rosiglitazone pioglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PIOGLITAZONE; PROTEINASE INHIBITOR; ROSIGLITAZONE; STAVUDINE; ZIDOVUDINE;

ARTICLE; BODY FAT; BODY MASS; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPOATROPHY; META ANALYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; VIRUS LOAD;

EID: 77951260843     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1101-39     Document Type: Article

References (38)

1. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. New Engl J Med. 2005;352:48-62. (Pubitemid 40075680)
2. Mynarcik D, Wei LX, Komaroff E, Ferris R, McNurlan M, Gelato M. Chronic loss of subcutaneous adipose tissue in HIV-associated lipodystrophy may not be associated with accelerated apoptosis. J Acquir Immune Defi c Syndr. 2005;38:367-371. (Pubitemid 40094119)
3. Roche R, Poizot-Martin I, Martin-El Yazidi C, Compe E, Gastaut J-A, Torresani J, Planells R. Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS. 2002;16:13-20. (Pubitemid 34062177)
4. Serghides L, Nathoo S, Walmsley S, Kain KC. CD36 deficiency induced by antiretroviral therapy. AIDS. 2002;16:353-358. (Pubitemid 34165366)
5. Miyaoka K, Kuwasako T, Hirano K, et al. CD36 defi ciency associated with insulin resistance. Lancet. 2001;357: 686-687. (Pubitemid 32206428)
6. Aitman TJ. CD36, insulin resistance, and coronary heart disease. Lancet. 2001;357:651-652. (Pubitemid 32206417)
7. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-anologue reverse- transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354:1112-1115. (Pubitemid 29452832)
8. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46: 716-723. (Pubitemid 34157656)
9. Mallon PW, Unemori P, Sedwell R, et al; SAMA Investigators. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis. 2005;191:1686-1696. (Pubitemid 40656757)
10. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1 infected men starting therapy. AIDS. 2003;17:971-979. (Pubitemid 36549708)
11. Haubrich RH, Riddler SA, DiRienzo AG, et al; AIDS Clinical Trials Group (ACTG) A5142 Study Team. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23(9):1109-1118.
12. Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid disorders, and body fat changes in antiretroviral-naïve subjects randomized to nelfi navir or efavirenz plus dual nucleosides. AIDS. 2005;19:1807-1818. (Pubitemid 41546599)
13. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profi le with abacavir as compared to stavudine: 96 week results of a randomized study. J Acquir Immune Defi c Syndr. 2007;44:139-147. (Pubitemid 46292215)
14. Arighu E, Duncan-Morin J, Sebring N, et al. Effi cacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med. 2000;133:263-274. (Pubitemid 30660298)
15. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajia N, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care. 1999;22:908-912. (Pubitemid 29241043)
16. Kawai T, Takei I, Oguma Y, et al. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism. 1999;48:1102-1107. (Pubitemid 29418278)
17. Chiquette E, Ramirez G, DeFronzo R. A meta- analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164:2097-2104. (Pubitemid 39419498)
18. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomized, double-blind, placebo-controlled trial. Lancet. 2004;363: 429-438. (Pubitemid 38210059)
19. Sutinen J, Häkkinen AM, Westerbacka J, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy: a randomized double-blind placebo-controlled study. Int Med Press. 2003;8:199-207. (Pubitemid 36960893)
20. Cavalcanti R, Raboud JM, Shen S, Kain K, Cheung A, Walmsley S. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis. 2007;195(12):1754-1761. (Pubitemid 46870247)
21. Hadigan C, Yawetz S, Thomas A, Havers F, Sax F, Grinspoon S. Metabolic effects of rosiglitazone in HIV .lipodystrophy: a randomized, controlled trial. Ann Intern Med. 2006;140:786-795.
22. Mulligan K, Yang Y, Wininger D, et al. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS. 2007;21:47-57. (Pubitemid 44912536)
23. Slama L, Lanoy E, Valanin MA, et al. Effect of pioglitazone on HIV-1 related lipodystrophy: a randomized doubleblind placebo-controlled trial (ANRS 113). Antiviral Ther. 2008;13:67-76. (Pubitemid 351541675)
24. Zeger SL, Liang KY. Longitudinal data analysis of discrete and continuous outcomes. Biometrics. 1986;42:121-130.
25. El Bejjani D, Tungsiripat M, Rizk N, et al. Rosiglitazone improves lipoatrophy in patients receiving thymidinesparing regimens. In : Program and abstracts from the 16th Conference on Retroviruses and Opportunistic Infections; 2009. Abstract 42LB.
26. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-1667. (Pubitemid 30015713)
27. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008: 1-128. Available http://www.aidsinfo.nih.gov/ ContentFiles/ AdultandAdolescentGL.pdf Accessed May 1, 2008. [Table 18, page 83]
28. Moyle G, Savin CA, Cartledge J, et al; RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043-2050. (Pubitemid 44611057)
29. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288:207-215. (Pubitemid 34755281)
30. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to Abacavir: the MITOX Extension Study. AIDS. 2004;18:1029-1036. (Pubitemid 38591194)
31. John M, McKinnon EJ, James IR, et al. Randomized, controlled, 48-week study of switching and/or protease inhibitors to combivir/Abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr. 2003;33:29-33. (Pubitemid 36547238)
32. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodefi ciency virusinfected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38:263-270.
33. Gelato MC, Mynarcik DC, Quick JL, et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defi c Syndr. 2002;31:163-170.
34. Mallon PWG, Sedwell R, Rogers G, et al; for the Rosey Investigators. Adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction. J Infect Dis. 2008;198:1794-1803.
35. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471. (Pubitemid 46919772)
36. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fi xed-dose zidovudine/lamivudine and efavirenz in antiretroviral- naïve patients: virologic, immunologic and morphologic changes - a 96 week analysis. J Acquir Immune Defi c Syndr. 2006;43:535-540.
37. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta analysis. JAMA. 2007;298:1189-1195. (Pubitemid 47403105)
38. Nagajothi N, Adigopula S, Balamuthusamy S, et al. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials. Am J Ther. 2008;15(6): 506-511.